期刊
ANTICANCER RESEARCH
卷 36, 期 9, 页码 4955-4959出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.11063
关键词
Metastatic colorectal cancer; cetuximab; panitumumab; KRAS; microRNA; miR-31-5p
类别
资金
- Roche
- Merck
- Amgen
- Czech Ministry of Health [16-31765A, MZ CR - RVO (MOU, 00209805)]
- Ministry of Education, Youth and Sports of the Czech Republic under project CEITEC [LQ1601]
- Czech Ministry of Education, Youth and Sports [NPU LO 1304]
- Czech Technological Agency: project TACR [TE02000058]
Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据